Administering AMD3100, a CXCL12 receptor, chemokine receptor 4 (CXCR4, SE = 13.1) inhibitor, inhibited CXCR4 in tumor cells and moreover induced rapid T-cell accumulation (Figure 2), which acted synergistically with the PD-L1 antibody to greatly diminish PDAC tumor cells [25,26]. Here, CXCR4 is linked to neoplasm.